YJL171C Antibody

What is YJL171c and why is it significant in antibody research?

YJL171c is a yeast glycoprotein found in Saccharomyces cerevisiae that contains multiple N-linked glycosylation sites at high density. Its significance in antibody research stems from its demonstrated cross-reactivity with broadly neutralizing antibodies such as 2G12, which typically targets HIV-1 envelope glycoproteins. This cross-reactivity occurs because the high-mannose-type oligosaccharides on YJL171c can mimic glycan structures found on viral proteins, making it valuable for studying carbohydrate-dependent epitopes and developing novel immunization strategies .

How are YJL171c antibodies typically generated for research purposes?

YJL171c antibodies are typically generated through synthetic peptide immunization approaches. In documented research, antibodies against YJL171c have been produced by:

• Synthesizing specific peptide sequences (such as "EVGDRVWFSGKNAPLADY") based on the YJL171c protein structure

• Coupling these peptides to carrier proteins like keyhole limpet hemocyanin (KLH)

• Immunizing animals (commonly rabbits) following a scheduled protocol:

  • Initial immunization with the antigen in complete Freund's adjuvant

  • Subsequent boosts with antigen in incomplete Freund's adjuvant at weeks 2, 4, and every 4 weeks thereafter

• Collecting sera one week after each boost

• Purifying the antibodies through immunoaffinity chromatography using the antigenic peptide coupled to SulfoLink gel

What is the relationship between YJL171c antibodies and HIV research?

YJL171c, along with other yeast glycoproteins (Ecm33, Gp38, and Gas1), has been identified as a protein that can be efficiently recognized by the broadly neutralizing antibody 2G12, which typically targets HIV-1 envelope glycoproteins. This cross-reactivity occurs because:

• Both YJL171c and HIV-1 gp120 contain a large number and high density of N-linked glycans

• When certain genes in the N-glycosylation pathway (Och1, Mnn1, and Mnn4) are deleted in yeast, the resulting glycan profile becomes predominantly Man₈GlcNAc₂, which resembles structures on HIV-1 envelope

• Glycosidase digestion abrogates this 2G12 cross-reactivity, confirming its carbohydrate-dependent nature

This relationship suggests that modified yeast proteins like YJL171c could potentially serve as molecular scaffolds that recapitulate carbohydrate-dependent epitopes found on HIV-1 Env proteins, potentially aiding in vaccine development .

How can YJL171c antibodies be utilized in the development of HIV vaccine candidates?

YJL171c antibodies can contribute to HIV vaccine development through multiple mechanistic approaches:

• Immunogen Design: YJL171c can serve as a molecular scaffold displaying glycan patterns similar to those on HIV-1 envelope glycoproteins. Research has shown that immunization with whole cells of mutant yeast (Δoch1Δmnn1Δmnn4) expressing proteins like YJL171c produces immune sera that cross-react with a broad array of HIV-1 and SIV Env glycoproteins .

• Epitope Mapping: YJL171c antibodies can help identify conserved glycan epitopes that might be targeted by broadly neutralizing antibodies. This mapping can guide rational design of HIV immunogens that present critical epitopes in an optimal conformation.

• Neutralization Breadth Analysis: By studying how YJL171c-induced antibodies neutralize diverse HIV strains, researchers can identify glycan patterns that confer broad protection, similar to how 2G12 circumvents obstacles by binding to conserved high-mannose oligosaccharides on gp120 .

• Carbohydrate Engineering: The understanding gained from YJL171c's glycan-dependent epitopes can inform strategies to engineer glycan shields that elicit broadly neutralizing antibody responses against HIV-1.

What experimental approaches can distinguish between protein-specific and glycan-specific binding of YJL171c antibodies?

Distinguishing between protein-specific and glycan-specific binding requires systematic experimental approaches:

• Glycosidase Digestion Assays: Treating YJL171c with enzymes like PNGase F or Endoglycosidase H that remove N-linked glycans will abolish glycan-dependent binding while preserving protein epitopes. Research has demonstrated that glycosidase digestion abrogates 2G12 cross-reactivity with yeast glycoproteins .

• Site-Directed Mutagenesis:

  • Mutate N-glycosylation sites (N-X-S/T motifs) without altering the protein structure

  • Compare antibody binding to wild-type and mutant proteins

  • A significant reduction in binding to mutants suggests glycan-dependent recognition

• Competitive Inhibition Assays:

  • Pre-incubate antibodies with free glycans of defined structure

  • Measure residual binding to YJL171c

  • Inhibition by specific glycans identifies the carbohydrate structures recognized

• Chemical Modification:

  • Perform periodate oxidation to modify carbohydrate structures while preserving protein epitopes

  • Compare antibody binding before and after treatment

• Lectin Competition:

  • Use lectins with known carbohydrate specificities to compete with antibody binding

  • Blockage by specific lectins indicates shared glycan epitopes

These approaches can be combined to generate comprehensive binding profiles that distinguish protein-specific from glycan-specific interactions.

What are the optimal conditions for generating YJL171c antibodies with high specificity and affinity?

Generating high-quality YJL171c antibodies requires careful optimization of multiple parameters:

Researchers should monitor antibody titers after each boost and assess specificity using both the immunizing peptide and native YJL171c protein to ensure optimal antibody production.

How should researchers optimize western blot protocols for detecting YJL171c in yeast samples?

Optimizing western blot protocols for YJL171c detection requires addressing several yeast-specific challenges:

• Sample Preparation:

  • Use mechanical disruption (glass beads) combined with detergent lysis

  • Include protease inhibitors to prevent degradation

  • For glycosylated YJL171c detection, avoid reducing agents that may alter epitope structure

• Gel Selection and Running Conditions:

  • Use gradient gels (4-12% or 4-20%) to accommodate heterogeneous glycoforms

  • Consider native PAGE if antibody recognizes conformational epitopes

  • For glycoprotein separation, lower voltage (80-100V) yields better resolution

• Transfer Optimization:

  • Use PVDF membranes for glycoproteins (better retention than nitrocellulose)

  • Increase transfer time (overnight at 30V) for efficient transfer of glycoproteins

  • Include 10% methanol in transfer buffer for improved binding

• Blocking and Antibody Incubation:

  • Use 5% non-fat milk or 3% BSA in TBS with 0.1% Tween-20

  • Optimize primary antibody dilution (typical range: 1:500-1:5000)

  • Incubate overnight at 4°C for maximum sensitivity

  • Include 0.1% SDS in antibody dilution buffer to reduce non-specific binding

• Detection Optimization:

  • Use high-sensitivity chemiluminescent substrates for glycoprotein detection

  • Consider extended exposure times (30 seconds to 5 minutes)

  • If background is high, increase washing steps (5× 5 minutes)

• Controls:

  • Include a wild-type yeast extract and Δyjl171c mutant extract

  • Use pre-immune serum as a negative control

  • Include PNGase F-treated samples to confirm glycoprotein identity

These modifications to standard western blot protocols can significantly improve detection of YJL171c in complex yeast samples.

How can researchers troubleshoot non-specific binding issues with YJL171c antibodies?

Non-specific binding is a common challenge when working with yeast protein antibodies. Systematic troubleshooting approaches include:

• Characterize Cross-Reactivity:

  • Test antibody against wild-type and Δyjl171c knockout yeast strains

  • Perform western blots with whole cell extracts to identify cross-reactive bands

  • Use mass spectrometry to identify cross-reactive proteins

• Antibody Purification Strategies:

  • Perform affinity purification using the immunizing peptide

  • Consider cross-adsorption against yeast extracts lacking YJL171c

  • Use protein A/G purification followed by size exclusion chromatography

• Blocking Optimization:

  • Test different blocking agents (milk, BSA, casein, commercial blockers)

  • Include 0.1-0.3% Tween-20 in blocking and washing buffers

  • Pre-incubate antibody with yeast extract from Δyjl171c strain to absorb cross-reactivity

• Buffer Modifications:

  • Increase salt concentration (150-500 mM NaCl) to reduce ionic interactions

  • Add 0.1% SDS to disrupt hydrophobic interactions

  • Include 1-5% glycerol to improve antibody stability

• Sample Preparation Refinements:

  • Use subcellular fractionation to enrich for YJL171c-containing fractions

  • Perform immunoprecipitation before western blot analysis

  • Consider native vs. denaturing conditions based on epitope characteristics

By systematically implementing these approaches while monitoring specificity through appropriate controls, researchers can significantly reduce non-specific binding issues.

What analytical methods are most effective for validating YJL171c antibody specificity in glycobiology research?

Validating antibody specificity for glycosylated YJL171c requires complementary analytical approaches:

• Genetic Validation:

  • Compare antibody reactivity between wild-type and Δyjl171c deletion strains

  • Test against yeast with mutations in specific glycosylation genes (Δoch1, Δmnn1, Δmnn4)

  • Assess binding to YJL171c overexpression strains

• Biochemical Validation:

  • Perform enzymatic deglycosylation with PNGase F, Endo H, or α-mannosidase

  • Compare binding to YJL171c expressed in different hosts with distinct glycosylation

  • Use lectin affinity chromatography to separate glycoforms before antibody testing

• Mass Spectrometry Analysis:

  • Perform immunoprecipitation followed by MS/MS analysis

  • Characterize glycan structures on immunoprecipitated proteins

  • Compare observed glycopeptides with predicted YJL171c glycosylation sites

• Competitive Binding Assays:

  • Pre-incubate antibodies with purified YJL171c or immunizing peptide

  • Measure inhibition of binding to target samples

  • Compare inhibition profiles with structurally related and unrelated molecules

• Glycan Microarray Analysis:

  • Test antibody binding to arrays of defined glycan structures

  • Compare binding profiles with known glycan-binding proteins

  • Assess cross-reactivity with mammalian glycans

Research has shown that glycosidase digestion abrogates cross-reactivity between yeast glycoproteins and antibodies like 2G12, confirming the carbohydrate-dependent nature of recognition . This type of analysis is essential for validating YJL171c antibody specificity in glycobiology research.

How can YJL171c antibodies be engineered for enhanced specificity in complex experimental systems?

Engineering YJL171c antibodies for enhanced specificity can leverage several advanced techniques:

• Computational Design Approaches:

  • Apply biophysics-informed modeling to identify and disentangle multiple binding modes

  • Use machine learning algorithms trained on experimental selection data to predict antibody specificity

  • Design antibodies with customized specificity profiles for particular ligand combinations

• Domain Engineering:

  • Create single-chain variable fragments (scFvs) from YJL171c antibodies

  • Generate bispecific antibodies combining YJL171c recognition with another specificity

  • Develop nanobody formats for enhanced tissue penetration and stability

• Affinity Maturation:

  • Perform phage display with YJL171c antibody libraries containing CDR mutations

  • Select variants under increasingly stringent conditions

  • Identify antibody variants with improved specificity and reduced cross-reactivity

• Glycan Recognition Enhancement:

  • Integrate binding domains from lectins or carbohydrate-binding modules

  • Engineer CDR regions to optimize interactions with specific glycan structures

  • Create triple tandem formats by repeating short DNA sequences, as demonstrated with llama nanobodies

• Cross-Reactivity Elimination:

  • Identify key residues mediating unwanted cross-reactivity

  • Perform site-directed mutagenesis to eliminate these interactions

  • Apply negative selection strategies during antibody development

Research has demonstrated that engineering antibodies in a triple tandem format can dramatically enhance effectiveness, as shown with llama nanobodies that achieved 96% neutralization of diverse HIV-1 strains . Similar approaches could enhance YJL171c antibody specificity and functionality.

What are the most promising research directions for applying YJL171c antibodies in cross-species glycobiology studies?

YJL171c antibodies offer several promising research directions for cross-species glycobiology:

• Comparative Glycomics Applications:

  • Map conserved glycan epitopes across evolutionary distant species

  • Identify glycan structures that facilitate cross-species pathogen recognition

  • Study evolutionary conservation of glycosylation pathways through epitope recognition

• Viral Glycobiology:

  • Explore similarities between yeast and viral glycan shields

  • Investigate how YJL171c antibodies cross-react with viral glycoproteins like HIV-1 gp120

  • Develop carbohydrate-targeting strategies for broad antiviral immunity

• Immunogen Design Platforms:

  • Use YJL171c as a scaffold for displaying conserved glycan epitopes

  • Engineer yeast strains with modified glycosylation to mimic mammalian patterns

  • Develop whole-cell immunization strategies to elicit antibodies against conserved glycan epitopes

• Diagnostic Applications:

  • Develop glycan-specific detection systems for pathogen identification

  • Create screening tools for glycosylation abnormalities across species

  • Generate cross-reactive diagnostic reagents for emerging pathogens

• Therapeutic Antibody Development:

  • Apply knowledge from YJL171c antibody recognition to design therapeutic antibodies

  • Target shared glycan structures on human pathogens

  • Develop antibody-based treatments against glycan-dependent diseases

Research has demonstrated that immune sera raised against engineered yeast cells cross-react with a broad array of mammalian cell-expressed Env glycoproteins from HIV-1 and SIV strains . This suggests that YJL171c antibodies could serve as valuable tools for studying conserved glycan structures across diverse biological systems.